Literature DB >> 27618769

Prostate cancer: More cycles of docetaxel improve survival.

Louise Stone.   

Abstract

Entities:  

Year:  2016        PMID： 27618769     DOI： 10.1038/nrurol.2016.181

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.

Authors:  Ellen S de Morrée; Nicholas J Vogelzang; Daniel P Petrylak; Nikolay Budnik; Pawel J Wiechno; Cora N Sternberg; Kevin Doner; Joaquim Bellmunt; John M Burke; Maria Ochoa de Olza; Ananya Choudhury; Juergen E Gschwend; Evgeny Kopyltsov; Aude Flechon; Nicolas van As; Nadine Houede; Debora Barton; Abderrahim Fandi; Ulf Jungnelius; Shaoyi Li; Jack Shiansong Li; Ronald de Wit
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777
  1 in total
  1 in total

1.  Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.

Authors:  Geetha Nalairndran; Ivy Chung; Azad Hassan Abdul Razack; Felicia Fei-Lei Chung; Ling-Wei Hii; Wei-Meng Lim; Chin King Looi; Chun-Wai Mai; Chee-Onn Leong
Journal:  J Cell Mol Med       Date:  2021-07-28       Impact factor: 5.310
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.